Insulet (PODD)
(Delayed Data from NSDQ)
$194.38 USD
-2.38 (-1.21%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $194.51 +0.13 (0.07%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth C Momentum C VGM
Brokerage Reports
0 items in cart
Insulet Corporation [PODD]
Reports for Purchase
Showing records 201 - 220 ( 344 total )
Company: Insulet Corporation
Industry: Medical - Products
Positive (Albeit Temporary) Implications of a 2-Year Suspension of the Medical Device Tax
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
October Neulasta Onpro Kit Symphony Health Sales Estimate Reflects Continued Solid Share Gains; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Q3 sales beat - could OmniPod diabetes become a means to an end in drug delivery?
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Improving Business Trends Tough To Ignore This Time; Raising PT to $44; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Drug Delivery and International Performing Very Well; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Insulin Pump Project: Historical survey of ~5,700 users, reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Ypsomed FY1H16 Results Suggest It Remains On Track To Grow Its OmniPod Installed Base by 40%; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Neulasta On-Body Injector Symphony Health Sales Estimate: September Data Suggests A Return to Solid Share Gains; Maintain OUTPERFORM and $40 PT
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
3Q15 Preview: MedTech Fundamentals Remain Intact Despite Market Volatility
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
3Q15 Preview: MedTech Fundamentals Remain Intact Despite Market Volatility
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Neulasta On Body Injector Symphony Health Sales Estimate
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Neulasta On Body Injector Symphony Health Sales Estimate
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
July Neulasta Sales Suggest Impressive OBI Adoption Representing 22% of Neulasta Franchise; Positive for PODD Drug Delivery; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
July Neulasta Sales Suggest Impressive OBI Adoption Representing 22% of Neulasta Franchise; Positive for PODD Drug Delivery; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Q2 - the mystery of US OmniPod sales versus patient adds; maintain HOLD
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Despite Some Confusion, The Message That Things Are Improving Is Clear; Raising PT to $40; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Q2 results ahead of estimates and survey of 5,500+ pump users (2007 - present)
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
2Q Beat And Favorable Guidance Suggest PODD Is Regaining Momentum; Historical Accounting Issue Is A Minor Distraction; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Amgen Highlights Solid Launch of Neulasta On- Body Injector (OmniPod inside)
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
2Q Beat And Favorable Guidance Suggest PODD Is Regaining Momentum
Provider: WEDBUSH SECURITIES INC.